Venoarterial-Extracorporeal Membrane Oxygenation Without Routine Systemic Anticoagulation Decreases Adverse Events
Patients supported on VA-ECMO without other indications for anticoagulation can be treated without systemic anticoagulation during their VA-ECMO course.
Joint Perfusion COVID-19 Task Force Webinar 5/14/2020
Join the Joint Perfusion COVID-19 Task Force for the next live webinar on Thursday, May 14 to hear from physicians from around the world on COVID-19 treatments, reopening ORs, and starting up CPB again.
Global Effort to Collect Data on Ventilated Patients With COVID-19
They called their study ECMOCARD, short for Extracorporeal Membrane Oxygenation for novel Coronavirus Acute Respiratory Disease.
Gas Exchange Calculation may Estimate Changes in Pulmonary Blood Flow during Veno-Arterial Extracorporeal Membrane Oxygenation in a Porcine model.
VCO2 of the lung correlated strongly with pulmonary blood flow. Our model could predict pulmonary blood flow changes within clinically acceptable margins of error.
Perfusion and EuroELSO: A Revolution In Evolution – Indeed an ongoing evolvement – Online adaptation
This is the Editorial to a special issue of Perfusion on ECLS in cooperation with EuroELSO.
Multi-Modal Characterization of the Coagulopathy Associated With Extracorporeal Membrane Oxygenation
Therapy protocols for treating extracorporeal membrane oxygenation-associated coagulopathy should be further validated in large-scale prospective clinical investigations.
Factors Associated With Survival Following Extracorporeal Cardiopulmonary Resuscitation in Children
Efforts to improve systemic output before and after institution of ECPR might mitigate some of the significant risk factors for mortality.
Multicenter Study on Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation
Center experience with postcardiotomy venoarterial extracorporeal membrane oxygenation may contribute to improved results.
Pre-Intubation Veno-Venous Extracorporeal Membrane Oxygenation in Patients at Risk for Respiratory Decompensation
Initiation of awake VV-ECMO is feasible and is safe before intubation and induction of anesthesia in patients at high risk for respiratory decompensation.
PaO2 Greater than 300 mmHg Promotes an Inflammatory Response During Extracorporeal Circulation in a Rat Extracorporeal Membrane Oxygenation Model
These data demonstrate that it is better to avoid administration of too much oxygen during ECMO to attenuate lung injury linked to generation of superoxide and the systemic inflammatory response.
A Dual-Lumen Bicaval Cannula for Venovenous Extracorporeal Membrane Oxygenation
This cannula introduces design qualities that may offer advantages for acute respiratory failure requiring venovenous ECMO.
ECMO as a Platform for Rapid Ammonia Removal in a Neonate With Multienzyme Urea Cycle Disorder
This case will add to the existing scant literature supporting the use of ECMO as a platform for rapid removal of serum ammonia.
Regional Planning for Extracorporeal Membrane Oxygenation Allocation During COVID-19
Drawing from a collaborative framework developed by one United States metropolitan area with multiple adult and pediatric extracorporeal life support centers, this article aims to inform decision-making around ECMO use during a pandemic such as COVID-19.
Out-of-Hospital Cardiac Arrest during the Covid-19 Outbreak in Italy
The cumulative incidence of out-of-hospital cardiac arrest in 2020 was strongly associated with the cumulative incidence of Covid-19, and the increase in the number of cases of out-of-hospital cardiac arrest over the number in 2019 followed the time course of the Covid-19 outbreak
A Narrative Review of Antithrombin Use During Veno-Venous Extracorporeal Membrane Oxygenation in Adults: Rationale, Current Use, Effects on Anticoagulation, and Outcomes
Antithrombin use in veno-venous extracorporeal membrane oxygenation should be investigated on the threshold for supplementation, dose, and time of administration.
Platelet Count and Function during Pediatric Extracorporeal Membrane Oxygenation
In this review, we provide an overview of hemostatic alterations during ECMO, changes in platelet count and function, platelet monitoring techniques, bleeding risk, and future needs to best optimize patient management and care.
Nationwide system to centralize decisions around ECMO use for severe COVID-19 pneumonia in Japan (Special Correspondence)
We have collected a total of 26 patients with COVID-19 who required extracorporeal membranous oxygenation (ECMO).
Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in COVID-19: Experience with 32 patients
These initial data may provide useful information to help define the best strategies to care for these challenging patients, and may also provide a framework for much-needed future research about the use of ECMO to treat patients with COVID-19.
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
This case series provides characteristics and early outcomes of sequentially hospitalized patients with confirmed COVID-19 in the New York City area.
COVID-19 Respiratory Failure: Targeting Inflammation on VV-ECMO Support
We present the first successful case of VV-ECMO support to recovery of COVID-19 respiratory failure in North America.
Prognosis when Using Extracorporeal Membrane Oxygenation (ECMO) for Critically Ill COVID-19 Patients in China: a Retrospective Case Series
As anticipated, COVID-19 is a pandemic; all healthcare resources are stretched so that ECMO is not a therapy to be rushed to the frontline. Therefore, interim treatment guidelines of recommending ECMO for critically ill COVID-19 patients should be taken cautiously.
CytoSorbents Devices Wins Emergency Approval to Treat COVID-19 Patients
The Food and Drug Administration says it granted Emergency Use Authorization for CytoSorbent’s (NASDAQ:CTSO) CytoSorb device to treat patients with confirmed Covid-19 admitted to the ICU with confirmed or imminent respiratory failure.
Compassionate Use of Remdesivir for Patients with Severe Covid-19
We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2.
Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19
We describe a patient with Covid-19 and clinically significant coagulopathy, antiphospholipid antibodies, and multiple infarcts. He was one of three patients with these findings in an intensive care unit designated for patients with Covid-19.